We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of mol... Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States. Show more
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment...
false 0001583648 0001583648 2023-12-15 2023-12-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR...
0001583648 PIERIS PHARMACEUTICALS, INC. false --12-31 Q3 2023 0.3 0.7 0.7 0.3 2 12.5 0 14.2 6.8 300,000,000 98,851,927 74,519,103 0.001 10,000,000 15,617 15,617 15,617 0.001 85 85 85 4,026 4,026 4...
230831 8-K/A (Retention Benefits) true 0001583648 0001583648 2023-07-17 2023-07-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT...
As filed with the Securities and Exchange Commission on August 10, 2023 Registration No. 333- ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0245 | -11.7224880383 | 0.209 | 0.22 | 0.179 | 1188964 | 0.18882317 | CS |
4 | 0.0155 | 9.17159763314 | 0.169 | 0.279 | 0.155 | 1185323 | 0.1973073 | CS |
12 | 0.0069 | 3.88513513514 | 0.1776 | 0.279 | 0.1485 | 602336 | 0.18799293 | CS |
26 | -0.1155 | -38.5 | 0.3 | 0.335 | 0.1361 | 579036 | 0.20195392 | CS |
52 | -1.0955 | -85.5859375 | 1.28 | 1.52 | 0.1361 | 1430592 | 0.3309548 | CS |
156 | -2.4055 | -92.8764478764 | 2.59 | 6.15 | 0.1361 | 1717340 | 2.69471666 | CS |
260 | -2.9755 | -94.1613924051 | 3.16 | 6.2 | 0.1361 | 1217607 | 2.81068427 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions